Cytisine
Phase 3Small molecule
Cytisine is one of 44 small molecule programs targeting Screening. It is currently in Phase 3.
3
Indications
17
Total Trials
4
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
34 competitors in Smoking Cessation
#DrugCompanyPhaseTrials
1Nicorette
PfizerApproved
Chantix
PPrism Pharmaceuticals
Approved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Approved
Lunesta
Akero TherapeuticsApproved
Viagra
VViatris Specialty LLC
Approved
Nicotine Free Cigarettes
PfizerPhase 3
Wellbutrin
GSKPhase 3
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Inderal
WWyeth-Lederle Vaccines
Approved
Nicotine Replacement
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Smoking Cessation6 trials
Smokers3 trials
Screening1 trial
Screening and Multiple Intervention on Lung Epidemics
Active, not recruiting·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03654105·2,000 enrolled
4 more indications
Tobacco1 trial
Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV)
Completed·—·Phase 2/3·NCT02797587·400 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cytisine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAchieve Life Sciences